POPULARITY
47 episodes with stroke foundation
2 episodes with stroke foundation
4 episodes with stroke foundation
3 episodes with stroke foundation
2 episodes with stroke foundation
2 episodes with stroke foundation
2 episodes with stroke foundation
3 episodes with stroke foundation
2 episodes with stroke foundation
He is “The Man for All Seasons”.Name the sport and Rod Black has more than likely called the game.For 40 years, the award-winning broadcaster has had a front row seat and provided a soundtrack to many of Canada's greatest sports moments.From his early days as a young reporter at CKY TV in Winnipeg to his network commitments as a host and play by play announcer with CTV and TSN, Black has done it all. From NHL hockey to the NBA, Major League Baseball to the NFL and CFL, PGA & LPGA golf, World Championship boxing, ATP and WTA tennis, international figure skating, Indy Car and Formula One auto racing, the Masters, the Kentucky Derby, World Cup Soccer, speedskating, cycling, Canadian & USA college sports and of course both the Summer and Winter Olympics where Black not only hosted prime time shows in 1992 and1994 but also called several historic gold medals in 2010 and 2012.A consummate professional who displays passion and excitement in all that he does, Black is a nine time Canadian Screen Award & Gemini nominee. In 2005, Rod received the Sports Media Canada award for Most Outstanding Broadcaster.Inducted into the media wing of the Manitoba Sports Hall of Fame, Black's broadcasting abilities are not limited to the sports world. The ultra-adaptable announcer is a popular guest speaker, a voice and film actor, an author, and the former co-host of Canada AM-Canada's most-watched national morning show.Despite his chaotic work schedule Rod still has found time to lend his voice and donate his time to a great number of Canadian charities – Special Olympics, Sick Kids Hospital, Childrens Aid Foundation, Easter Seals, United Way, Right to Play, Pro Action Cops and Kids, Kids Help Phone, Canadian Cancer Society, CNIB, CAMH, the Heart and Stroke Foundation, and many more.An honorary spokesperson and ambassador for Plan Canada, Rod has received the Queen's medallion and Diamond Jubilee medal for volunteerism.When asked what his favorite moment has been in his acclaimed career, Rod pauses and says, “The next one. Truly, I absolutely love every memory, but I also wake up every day knowing that there are new great memories to discover. That is what sport teaches us. To enjoy the moments and create new ones. Learn all the lessons from these games – good and bad - and hopefully adapt them into our day to day lives. Nothing can do that like sport.”#rodblack #mediapersonality #playbyplayannouncer #chrispomay #livewithcdp #barrycullenchevrolet #cebl #scarboroughshootingstarshttps://beacons.ai/chrisdpomayhttps://www.cameo.com/chrispomayhttps://www.barrycullen.com/Want to create live streams like this? Check out StreamYard: https://streamyard.com/pal/d/54200596...
This week we meet some non-voters in northern Ontario, Sudbury NHLer Nick Foligno and his wife Janelle talk about becoming Heart and Stroke Foundation ambassadors, a look at how the health centre on Manitoulin keeps its emergency room open, we hear about a new card game company in Sudbury, and the Baxter Cup marks a 100 year rivalry between the curling clubs in Espanola and Little Current.
Jessica Pang-Parks is a volunteer engagement thought leader who helps organizations build trust, create impact, and inspire belonging. She is the recipient of the 2021 Alison Caird Young Leader Award in recognition of her leadership and excellence in volunteer engagement and the recipient of the 2023 VMPC Exemplary Leader Impact Award in recognition of her contributions to the field as a mentor, leader, trainer, and advocate.Jessica earned her CVA credential in April 2023 and has facilitated Fleming College's Volunteer Management: Spectrum of Engagement course since May 2022. She has held professional volunteer and community engagement roles at Crohn's and Colitis Canada, Pathways to Education Canada, the Heart & Stroke Foundation, Volunteer Toronto, and WWF-Canada.Jessica has the privilege to work on the traditional land of the Huron-Wendat, the Seneca, and the Mississaugas of the Credit. Learn more about Jessica at www.learnwithjpp.com.In this episode of The Nonprofit Insider Podcast, we dive into the volunteer side of the nonprofit world with volunteer engagement thought leader Jessica Pang-Parks. As the recipient of multiple leadership awards and a CVA credential holder, Jessica brings a wealth of knowledge on how nonprofits can build trust, create impact, and inspire belonging through effective volunteer management.We explore:Jessica's “State of the Union” on the current state of volunteerism.The unique challenges volunteer managers face and whether they're underappreciated.Her personal journey into consulting and the strategies she uses to combat nonprofit burnout.Key insights for hiring the right volunteer management consultant.Her outlook on nonprofit priorities in 2025.A captivating #NonprofitHorrorStory that sheds light on the realistic challenges behind the scenes.Whether you're an executive leader, board member, or volunteer coordinator, Jessica's insights will help you reimagine the role of volunteer engagement in your organization.Episode BreakdownState of the Nonprofit Volunteer Space – Jessica's take on how volunteer engagement is evolving.Challenges for Volunteer Management Leaders – Exploring the complexity and undervaluing of this critical role.Getting to Know Jessica – Her personal journey into volunteer engagement leadership and consulting.Burnout & Beyond – Insights into the growing issue of burnout among nonprofit professionals.Hiring a Volunteer Management Consultant – What to consider for ROI and organizational fit.Looking Ahead to 2025 – Jessica's advice on key priorities for nonprofit leaders this year.#NonprofitHorrorStory – A behind-the-scenes look at real-life mishaps in the nonprofit world.Connect with JessicaWebsite: www.learnwithjpp.com
Trey and Brian lace up their sneakers and hit the road with inspiring ultramarathoner Ryan Keeping. Ryan Keeping is a Canadian ultramarathoner who devoted himself to running coast-to-coast across his home country in under 100 days to honor the memory of Terry Fox and raise funds and awareness for the Heart and Stroke Foundation. During his historic and inspiring journey, he not only broke the limits of what he once thought was possible, but raised more than $250,000. Brian Phelps is an American radio personality, actor, and comedian best known for co-hosting the nationally and globally syndicated Mark & Brian Morning Show in Los Angeles for 25 years. As the co-lead of his own television series, with multiple roles in movies, and a Star on the Hollywood Walk of Fame, Phelps is also an inductee in the Radio Hall of Fame.Trey Callaway is an American film and TV writer and producer who wrote the hit movie I Still Know What You Did Last Summer, and has produced successful TV series like CSI:NY, Supernatural, Rush Hour, Revolution, The Messengers, APB, Station 19 and 9-1-1 LONE STAR. He is also a Professor at USC.___________________________________Make sure to follow us on social media at:begoodhumanspodcast.cominstagram.comtiktok.comthreads.netfacebook.com
See omnystudio.com/listener for privacy information.
My guest today is Trisha Fuller. Trisha Fuller is a Master Hypnotist/ NLP Practitioner, Trainer and International Speaker. Owner of Sherwood Park Hypnosis Center and The Canadian Hypnosis Academy. Trisha is passionate about helping others achieve their goals and design their successful future with hypnosis and NLP skills with private online sessions, corporate trainings, seminars and courses. Her inspiration and motivation stems from her own personal triumphs with hypnosis, Quitting Smoking and Hypnotic Childbirth. These successes inevitably changed the course of her life. Once a Laboratory and X-ray Technician, now a successful business owner with multiple clinic locations and a vocational school. Her teaching background is enhanced from years of teaching First Aid and CPR with the Canadian Red Cross and the Heart and Stroke Foundation, as well as Hypnosis for Childbirth with Hypnobabies. As a wife and mother of 3, living in a remote rural location she has had to learn to become curious and discover alternatives to building her business, balancing career and family, while commuting. This has broadened her perception of opportunities that people truly have. Helping clients, students and entrepreneurs, find their unique solutions, using hypnosis and NLP is her main focus. In this episode we discuss hypnotherapy, NLP, forgiveness, transformation and asking for help.Website - https://learnhypnosis.ca/IG - https://www.instagram.com/learnhypnosis.ca/FB - https://www.facebook.com/trisha.fuller.5/LinkedIn - https://www.linkedin.com/in/canadianhypnosisacademy/YouTube - https://www.youtube.com/@LearnHypnosis.caTrishaFullerX (Twitter) - https://x.com/hypnosisablearnIn this episode you will learn:1. What some common misconceptions about Hypnosis and NLP.2. The difference between a Hypnotherapist and a Master Hypnotherapist.3. Some of the most common reasons that people use Hypnotherapy. "Let's just start at the beginning. There is definitely basic hypnosis. Like you just learn the actual skills and then there's like clinical, there's advanced hypnosis, NLP practitioner, NLP master pack, all of these things." - 00:05:03"I'm a guide with a very specific tool set. And I think this is a future question for you. I don't do other modalities. I do hypnosis and NLP."- 00:25:49"You are the exact person you were meant to be. And everything that you have gone through was meant to happen and there's no shame and guilt in that." - 00:53:24Are you an author speaker coach or entrepreneur building a brand in today's very crowded marketplace? How do you stand out? Join me on Sept 27th and learn how to empower your message and shine as a guest on podcasts for just $97. Imagine stepping into that interview with clarity and conviction, connecting deeply with listeners who are eager to hear what you have to say. Imagine the satisfaction of knowing you've nailed it, leaving your audience inspired and wanting more. This would position you as an authority to thousands of people in your industry. Let's turn those nerves into excitement and make sure you shine on your podcast appearance. Together, we'll boost your confidence, polish your messaging for impact, and get you ready to deliver an interview that makes people fall in love with your from the first words. Ready to shine on podcasts? Let's do this! Click the link below to register.https://empowerographypodcast.com/empower-your-messageContact Brad:WebsiteInstagramLinkedInYouTubeX (Twitter)TikTok#empowerographypodcast #women #womensempowerment #empowherment #entrepreneurship #womeninentrepreneurship #empoweredwomen #empowerelevateeducate #findingyourpurpose #podcast #womensupportingwomen #soulalignment #heartcentered #selflove #resilience #personalgrowth #mindset #spirituality #healing #heartspace #forgiveness #hypnotherapy #masterhypnotherapist #NLP #alignment #transformation #intuition #askingforhelp #innergrowth #innerjourney #receiving
New research has found the number of Australians suffering a stroke each year is increasing. More than 45,000 Aussies experienced a stroke last year, equivalent to one person every 11 minutes. Luke Grant chats with CEO of the Stroke Foundation, Dr Lisa Murphy, to find out why stroke numbers are on the rise and to discuss this month's Stride4Stroke campaign, which sees participants set an activity goal to to lower their own stroke risk and raise funds for prevention and research. You can find more details here Listen to Luke Grant live on air from 9am Saturday & Sunday on Weekends with Luke Grant.See omnystudio.com/listener for privacy information.
See omnystudio.com/listener for privacy information.
In this powerful and inspiring bonus episode, we delve into the remarkable journey of Shruti Kothari, a 34-year-old actress and stroke survivor. On March 7, 2020, just before the pandemic shook the world, Shruti experienced a stroke while hosting friends at her apartment. Her left side went numb, and thanks to a quick-thinking friend trained in recognizing stroke symptoms, paramedics were called immediately. Shruti's story is not just one of survival but thriving against all odds. She talks about her rehabilitation process, an innovative program that helped her regain movement in her arm, and her determination to continue her acting career. Despite the challenges, Shruti's optimism and drive to give back to the community shine through. Additional ResourcesUHN's Stroke Prevention ClinicDr. Pikula was interviewed in the Your Complex Brain episode "The Rise of Stroke in Young Adults"UHN Foundation video "Shruti's journey back to the stage, with some help from Team UHN"Heart and Stroke Foundation of Canada – Women's Digital HubWorld Stroke Academy podcast featuring Dr. LindsayThe Your Complex Brain production team is Heather Sherman, Jessica Schmidt, Dr. Amy Ma, Kim Perry, Alley Wilson, Sara Yuan, Meagan Anderi, Liz Chapman, and Lorna Gilfedder.The Krembil Brain Institute, part of University Health Network, in Toronto, is home to one of the world's largest and most comprehensive teams of physicians and scientists uniquely working hand-in-hand to prevent and confront problems of the brain and spine, such as Parkinson's, Alzheimer's, epilepsy, stroke, spinal cord injury, chronic pain, brain cancer or concussion, in their lifetime. Through state-of-the-art patient care and advanced research, we are working relentlessly toward finding new treatments and cures.Do you want to know more about the Krembil Brain Institute at UHN? Visit us at: uhn.ca/krembilTo get in touch, email us at krembil@uhn.ca or message us on social media:Instagram - @krembilresearchTwitter - @KBI_UHNFacebook - https://www.facebook.com/KrembilBrainInstituteThanks for listening!
Join Manuel Arango, the director of Health Policy & Advocacy at the Heart and Stroke Foundation of Canada. We dive into the pressing issue of food marketing to children, exploring how these strategies impact kids' health and dietary habits. Manuel shares insights into the ongoing efforts to regulate unhealthy food and beverage marketing in Canada, why it's crucial for the government to act, and how parents can navigate the challenges posed by aggressive marketing tactics. Manuel Arango is the director of Health Policy & Advocacy at the Heart and Stroke Foundation of Canada. He discusses the KevinMD article, "Why my 5-year-old is helping with my PhD thesis." Our presenting sponsor is DAX Copilot by Microsoft. Do you spend more time on administrative tasks like clinical documentation than you do with patients? You're not alone. Clinicians report spending up to two hours on administrative tasks for each hour of patient care. Microsoft is committed to helping clinicians restore the balance with DAX Copilot, an AI-powered, voice-enabled solution that automates clinical documentation and workflows. 70 percent of physicians who use DAX Copilot say it improves their work-life balance while reducing feelings of burnout and fatigue. Patients love it too! 93 percent of patients say their physician is more personable and conversational, and 75 percent of physicians say it improves patient experiences. Help restore your work-life balance with DAX Copilot, your AI assistant for automated clinical documentation and workflows. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://www.kevinmd.com/cme I'm partnering with Learner+ to offer clinicians access to an AI-powered reflective portfolio that rewards CME/CE credits from meaningful reflections. Find out more: https://www.kevinmd.com/learnerplus
Matthew Pantelis speaks with Dr Lisa Murphy, CEO, Stroke Foundation who says more people are having strokes. Listen live on the FIVEAA Player. Follow us on Facebook, X and Instagram.See omnystudio.com/listener for privacy information.
This interview first aired on Tuesday the 6th of August, 2024 on ONE FM 98.5 Shepparton. One FM breakfast announcer Plemo interviews emma Dullard from the Stroke Foundation about National Stroke Week. She shares her story and talks how you can be involved with National Stroke Week. To find out more head to - https://strokefoundation.org.au/ Contact the station on admin@fm985.com.au or (+613) 58313131. Listen to One FM Breakfast with Plemo weekdays on 98.5 One FM 6am-9am. The ONE FM 98.5 Community Radio podcast page operates under the license of Goulburn Valley Community Radio Inc. (ONE FM) Number 1385226/1. PRA AMCOS (Australasian Performing Right Association Limited and Australasian Mechanical Copyright Owners Society) that covers Simulcasting and Online content including podcasts with musical content, that we pay every year. This licence number is 1385226/1
Stroke Foundation NZ - Nicky Mayne, General Manager Community Services with Stroke Foundation NZ provides an overview of changes to the service that are designed to better equip other service providers in the health space to provide stroke support in the community. This show was broadcast on OAR 105.4FM Dunedin - oar.org.nz
Ryan Keeping of Halifax ran 75 kilometers a day to get from St. John's, Nfld., to Victoria, B.C., to complete his cross-country journey in just 99 days. He joins host Jeff Douglas to talk about why it was important to him to raise money for the Heart and Stroke Foundation.
How can a person make a difference in the world? Ryan Keeping, a 27-year-old from Halifax, has been running across Canada to find that answer. Starting on April 1st from St. Johns, Newfoundland, Ryan aims to cover 7,386 km in 99 days, running 75 km daily to raise funds for the Heart & Stroke Foundation of Canada. Matthew Harrison ran with Ryan to hear his story.
In this episode, host Victoria Emslie is joined by Alison Twiner, a dedicated past Chair of the National Board, and Robyn Jones-Murrell, Senior Vice President for Western Canada, both from the Heart & Stroke Foundation. Together, they share their unique journeys and profound impact on the foundation's mission. Robyn recounts her unexpected path to the foundation, highlighted by her father's dramatic survival of a Widowmaker heart attack just days before her interview. Alison reflects on her lifelong commitment to heart and stroke causes, from childhood canvassing with her mom to leading digital transformation on the board. They also emphasize how the Heart & Stroke Foundation drives vital research, advocates for life-saving policies, and tackles critical issues such as women's heart health and bystander CPR.
A stroke happens when there is a sudden blockage of blood flow to the brain or bleeding in the brain, which can result in symptoms such as numbness or weakness, trouble speaking, confusion, or dizziness. The type of symptoms one might experience depends largely on the type of stroke, and the area of the brain affected. But one thing is clear – despite the many advances in stroke care over the past 30 years, it's women who often suffer the most. In today's episode, we discuss why women are more susceptible to stroke, what the unique risk factors are, and what women need more of to help them recover, not only from the medical condition, but the impacts to their careers, their mental health and their families. Featuring: Dr. Aleksandra Pikula, MD, PhD, is a neurologist and clinician-investigator at UHN's Krembil Brain Institute and the newly appointed Jay and Sari Sonshine Chair in Stroke Prevention and Cerebrovascular Brain Health at UHN. Dr. Pikula advocates for a holistic approach to brain care, specifically targeting stroke and dementia prevention during midlife through evidence-based lifestyle medicine pillars.Patrice Lindsay, PhD, is currently the Lead for the People With Lived Experience (PWLE) Engagement and Stroke Strategy at the Heart and Stroke Foundation of Canada. Dr. Lindsay leads strategic directions for health systems design and change for people with stroke and heart conditions across Canada and internationally. Shruti Kothari is an actress born, raised, and residing in Toronto. Her career was focused largely on Shakespeare and Musical Theatre until her life took an unexpected turn when she suffered a life-altering brain hemorrhage and stroke at the age of 30. Over the past four years, Shruti has focused on reshaping her life and raising awareness about brain injuries in younger people. Additional resources: UHN's Stroke Prevention ClinicDr. Pikula interviewed in the Your Complex Brain episode “The Rise of Stroke in Young Adults”UHN Foundation video “Shruti's journey back to the stage, with some help from Team UHN”Heart and Stroke Foundation of Canada – Women's Digital HubWorld Stroke Academy pThe Your Complex Brain production team is Heather Sherman, Jessica Schmidt, Dr. Amy Ma, Kim Perry, Sara Yuan, Meagan Anderi, Liz Chapman, and Lorna Gilfedder.The Krembil Brain Institute, part of University Health Network, in Toronto, is home to one of the world's largest and most comprehensive teams of physicians and scientists uniquely working hand-in-hand to prevent and confront problems of the brain and spine, such as Parkinson's, Alzheimer's, epilepsy, stroke, spinal cord injury, chronic pain, brain cancer or concussion, in their lifetime. Through state-of-the-art patient care and advanced research, we are working relentlessly toward finding new treatments and cures.Do you want to know more about the Krembil Brain Institute at UHN? Visit us at: uhn.ca/krembilTo get in touch, email us at krembil@uhn.ca or message us on social media:Instagram - @krembilresearchTwitter - @KBI_UHNFacebook - https://www.facebook.com/KrembilBrainInstituteThanks for listening!
From the laboratory to saving lives, this episode brings together three outstanding researchers from the University of Saskatchewan's Department of Anatomy, Physiology, and Pharmacology (APP) as they discuss their work and its implications for cardiac care. Dr. Michelle Collins, Dr. Scott Widenmaier, and Dr. Changting Xiao are all recent recipients of research grants from Heart & Stroke (formerly the Heart and Stroke Foundation of Canada). In Canada, one per cent of newborns have congenital heart defects. Thanks to advances in cardiac care, up to 85 per cent of these infants now survive to adulthood. Meredith Rhinas is one of those survivors. Diagnosed with aortic stenosis as an infant, by her thirties, she received conflicting guidance from cardiologists, and risked congestive heart failure giving birth. She underwent open-heart surgery to replace her aortic valve after delivering her fourth and final child, surgery that led to further complications caused by an oversized replacement valve. “That's a piece that is missing,” said Rhinas, who said most heart attack protocols still skew toward older men -- often overlooking younger patients and women of childbearing age. “I want the research to catch up." In this episode Dr. Michelle Collins, an expert in the molecular basis of cardiac development and function, discusses her work on congenital heart defects, seeking to understand what makes a heart beat. With her lab's focus on the movement of calcium ions and their role in heart function, Collins emphasizes the importance of understanding cardiac arrhythmias, particularly atrial fibrillation, which has traditionally been viewed as an electrical disease. “There's a significant contribution from genes that are really early transcription factors that build the heart during development,” Collins said. Dr. Scott Widenmaier's work looks at the liver, an organ he has dubbed "the Amazon of our body", as it presents our first line of defence against stressors, which often are a precursor to heart disease. In this episode, Widenmaier explains how and why those stress defense mechanisms can be harnessed to prevent the conditions that lead to heart disease and stroke. "Things are happening way quicker, way faster, and the technology's there. The ability to find the genetic variants is there," Widenmaier said. "There's hope in that.” Dr. Changting Xiao, known for his innovative work on gut physiology and metabolism, explores the gut's role in lipid processing and its implications for heart disease. "We want to understand how these enterocytes process the fat inside the cells," said Xiao. His research aims to identify druggable targets within the gut to correct lipid disorders and combat heart disease. Xiao passionately believes in the ancient wisdom that "all disease starts in the gut," asserting that a deeper understanding of gut functions can lead to breakthroughs in preventing and treating heart conditions. "Every small step we move forward looks small, but in the long run we build knowledge and we move forward," said Xiao. His laboratory is now one of only a handful worldwide specializing in being able to see both sides of nutrients entering and leaving the gut. With awards being administered through a rigorous national peer-review process, Carolyn Cyr praised Saskatchewan's researchers for rising to the top. She's the province's Director of Health Policy and Systems for Heart & Stroke. "It's definitely something to celebrate,” said Cyr. "It's a testament to the excellent research they're doing and the high calibre of their applications that we have three researchers from the same department who are able to be funded.”
With Carissa Gravelle at Heart and Stroke Foundation. The link between experiences of discrimination and your health and wellness is undeniable. It's all about the “social determinants of health”. Discrimination based on gender and other connected factors like our race and ability impacts our health in so many ways. For example, we get treated differently based on our gender in healthcare settings. Our access to relevant health services and options differs wildly depending on our gender. Even the medical research that gets funded and acted on depends on our gender. In honour of International Day of Action for Women's Health, we're focusing on gender and health matters we may know bits and pieces of but probably need to learn more about. Our guest Carissa Gravelle is passionate about anti-racism, diversity, inclusion, young people, under-represented populations, mental health, and wellness. Carissa has worked in the non-profit sector for over a decade spearheading equity, diversity, inclusion, and access initiatives. Carissa works to advance health equity for marginalized populations and believes in the importance of educating through storytelling and meaningful conversations to change perceptions and inspire social change. Relevant Links: Heart and Stroke Foundation Episode Transcripts Please listen, subscribe, rate, and review this podcast and share it with others. If you appreciate this content, if you want to get in on the efforts to build a gender equal Canada, please donate at canadianwomen.org and consider becoming a monthly donor. Facebook: Canadian Women's Foundation LinkedIn: The Canadian Women's Foundation Instagram: @canadianwomensfoundation TikTok: @cdnwomenfdn X: @cdnwomenfdn
Welcome to my interview with Alice Johnson. Alice is a registered nurse, triathlete, marathon runner, a mum of 2 awesome boys, and now an ultra runner who recently complete the 100km Buffalo Stampede in Bright, Victoria. In this conversation you'll hear how having a stroke at the age of 29 only 5 days after giving birth to her second child lead Alice into discovering running. And how a few words form a Dr put her on a journey to becoming an endurance athlete with the biggest smile and biggest heart of anyone you are likely to meet. Now an ambassador for the Stroke Foundation, Alice is raising awareness of stroke and is especially focused on helping young stroke survivors to have a role model - to show them that anything is possible, and know they are not alone. Please enjoy my interview with Alice Johnson. Follow Rob here: Facebook: https://www.facebook.com/profile.php?id=100089043347091 Instagram: https://www.instagram.com/robmasonruns/
Nurse Silvia Craucamp | Health Promotion Officer with the Heart and Stroke Foundation Alot of work is being done to highlight the negative effects of raised blood pressure on overall health and to specifically call attention to the relationship between excessive salt intake and hypertension. To this end, the Heart and Stroke Foundation South Africa (HSFSA), the National Department of Health (NDOH), World Action on Salt, Sugar and Health, Unilever and other important local and international partners have come together to celebrate World Hypertension Day (WHypD) tomorrow (17 May) in alignment with Salt Awareness Week from 15 - 21 May. World Hypertension Day is a World Hypertension League initiative. The primary aim of this world health event is to increase the awareness of the dangers of high blood pressure or hypertension in populations around the world with the theme “Measure your blood pressure accurately, control it, live longer". There is a focus on combating low awareness rates worldwide, especially in low to middle income areas, and accurate blood pressure measurement methods. Moreover, there is greater mobilisation globally, to ensure that those individuals who are diagnosed with hypertension and are on medication, are aware that they need to take their medication as prescribed in order to effectively control their condition.See omnystudio.com/listener for privacy information.
The Stroke Foundation wants mandatory standards introduced to reduce the amount of salt in processed foods, which it says will save thousands of New Zealand lives lost or impacted by strokes each year. The foundation says many people are consuming much more than the recommended 5-gram daily intake daily with most of the salt content hidden in the everyday foods we eat. It is calling on the government to regulate the industry and to make it easier for people to eat less salt. Jess Winchester, general manager of marketing and fundraising at Stroke Foundation of New Zealand, joins Jesse.
There are calls for the government to better regulate salt content in our processed foods. Research from Otago and Auckland universities reveals about two thirds of packaged foods on supermarket shelves exceed the World Health Organisation benchmark. Stroke Foundation General Manager Jess Winchester says one fifth of New Zealanders already have high blood pressure. She told Mike Hosking that the government needs to begin holding food manufacturers to the WHO sodium benchmarks. Winchester says people shouldn't be risking their lives every time they bite into their favourite pie. LISTEN ABOVE See omnystudio.com/listener for privacy information.
In this episode we dive more into the definition of “plucky” –what it is and isn't. I give examples of plucky people including my friend, Mandy, and Susan Atkey, who writes about her stroke recovery on Medium. She is swimming 100k and raising awareness and funds for the Heart & Stroke Foundation. Learn to be plucky like a baby duck learns to fly–by winging it. Watch baby ducks courageously jumping from their nest here. Connect with me, Coach Carrie, @carriejobradley. If you're doing something that requires determined courage, use the hashtag #pluckynotperfect and tag me. I always love to reshare and cheer you on.
What a new report tells us about Cardiac Arrest A new report from the Heart and Stroke Foundation finds that this potentially fatal event occurring outside a hospital is far more prevalent than we thought. Cardiologist Dr. Christopher Labos tells us simple training could save lives. Are you exercising right after the age of 50?
Does caffeine make you jittery? Can you drink it and go straight to bed?Are you a "coffee person"?That answer might have something to do with your genes. And that's what we're talking about today with Registered Dietitian Devon Peart. It's an insightful conversation with lots of useable nuggets, and I hope you enjoy it as much as I did!We're covering:the contradictory information around caffeine's benefits how caffeine works and the adenosine connectionhow genetics play a part when it comes to caffeinewhat genetic testing iscoffee chat Devon's "thing" when it comes to sleepDevon's feelgoodthingAbout Devon:Devon Peart is a Registered Dietitian and Nutritionist with Cleveland Clinic Canada's Executive Health program, lead of the Nutrigenomics program at Cleveland Clinic, and a private nutrition coach. Devon is dedicated to helping her patients live their healthiest lives. She specializes in brain health, nutrigenomics, hormone health, sport nutrition and heart health. Devon has written extensively for a variety of outlets including Huffington Post Canada, and is frequently interviewed for print and web platforms including Costco, Narcity Toronto, Yahoo Canada and Cleveland Clinic Health Essentials. She has worked in both private and public sectors including Mount Sinai Hospital and Heart and Stroke Foundation of Canada, and as an Instructor in the Fitness and Health Promotion program at Humber College. After completing a Bachelor of Arts in Political Science and Sociology at the University of Toronto, Devon decided to follow her passion for health. She obtained a Bachelor of Applied Science in Nutrition from Toronto Metropolitan University, and then returned to University of Toronto where she completed a Master of Health Science in Nutrition, and the Collaborative program in Women's Studies. Devon believes there is not one “right” way to eat; including good quality, minimally processed foods is key. She takes a holistic approach to nutrition that incorporates lifestyle, stress management and always—enjoyment of food! When she's not working, Devon enjoys yoga and strength training. She loves literary fiction, seeing live music, spending time with friends, and with her husband and three sons. Devon's Instagram: @devon_peartDevon's Email: peartd@ccf.orgThe Key Moments in this episode are:00:02:15 - my clumsy start to the day 00:05:50 - caffeine studies confusion00:10:00 - different caffeine genes00:11:30- how Devon does genetic testing00:19:00 - how long to test a caffeine break for 00:25:00 - amount of coffee to drink depending now how you process caffeine00:20:35 - Devon's thing00:33:30 - Devon's feelgood thing00:34:00 - what to remember when it comes to genetics and your health
This week on the podcast I speak to dr Scott Lear, professor in at Simon Fraser University on mental health, lifestyle strategies and speaking out in order to help foster awareness and acceptance amongst those around you. We spent most of our time discussing Professor Lear's own depression diagnosis after several years of feeling down but for no (what Scott calls) good reason for it. We discuss the stigma that is attached to mental health diagnoses and the impact this can have on people talking about their mental health. We talk about the strategies he employed (both professional and also personal) to help recover from it and how important it was for him to receive treatment even though he was doing a lot of what is recommended we do to help our mental health (like exercise, diet etc). and how this led him to become interested in (and an advocate for) the impact that lifestyle has on mental health.Dr Scott Lear is a Professor in the Faculty of Health Sciences at Simon Fraser University and holds the Pfizer/Heart and Stroke Foundation Chair in Cardiovascular Prevention Research at St. Paul's Hospital. He is also a member of the Division of Cardiology at Providence Health Care.Over the past 20 years, he's been conducting research in the prevention and management of heart disease focusing on supporting healthy lifestyles and improving access to timely health care.In addition to publishing over 160 research papers, his work has been featured in various media outlets including The Vancouver Sun, The Conversation, The Heart and Stroke Foundation, CityTV and Global News. He also has an active blog and regularly podcasts on issues to do with health, including heart health, mental health and overall health. Link is below for his blog.https://www.sfu.ca/fhs/about/people/profiles/scott-lear.htmlBLOG https://drscottlear.com/category/patient-journey/ Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwillidenSave 20% on all NuZest Products WORLDWIDE with the code MIKKI at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comCurranz supplement: MIKKI saves you 25% at www.curranz.co.nz or www.curranz.co.uk ooff your first order
Charles Tam is the Director of Regulatory Affairs and a member of the Leadership Team at Edwards Lifesciences. He joins Linda today on the Lifesciences Professional Podcast to explain what Regulatory Affairs is and the potential career opportunities. Charles joined Edwards Lifesciences in 2014 and previously held progressive regulatory leadership roles at Abbott Laboratories, Johnson & Johnson Medical Companies, and Becton-Dickinson and Company Inc. Bridging experiences across academia, government, and the private sector, Charles is passionate about enabling greater access to clinical research and medical technology innovation for all Canadians. He is a Sub-Committee Chair and Regulatory Affairs Steering Committee member at MedTech Canada and is an Advisor at the University of Toronto's Health Innovation Hub (H2i), part of the Temerty Faculty of Medicine. Previously, he has served as a Councillor on the Coronary Artery and Vascular Disease Council at the Heart and Stroke Foundation of Canada, retained on the roster of experts for Investigational Testing by Health Canada's Health Products and Food Branch, and served as an elected Senator on the Toronto Metropolitan University's Senate (formerly Ryerson University). Charles obtained his MBA at the Toronto Metropolitan University (formerly Ryerson University) and holds an Honours BSc from the University of Toronto.
Subscribe to Mamamia The story of Jessica Watson's unbelievable solo sailing trip around the world at age 16 has been etched into Australian lore. More than a decade after that achievement, the details of how she survived 210 days of severe storms, isolation and even her boat flipping upside down 15 feet underwater, will astound you. She still holds the record for youngest person to sail solo, nonstop and unassisted around the world. No mean feat. But that trip wasn't the only storm the now 29-year-old has had to endure. Speaking to Claire Murphy, Jessica reveals the challenge of working on her newly released Netflix biopic True Spirit, while her life was falling apart. This is Jessica Watson's story. THE END BITS: With thanks to Jessica Watson. Watch True Spirit on Netflix. Find out more about the Stroke Foundation, and how to check your blood pressure. Feedback? We're listening! Call the pod phone on 02 8999 9386 or email us at podcast@mamamia.com.au Need more lols, info, and inspo in your ears? Find more Mamamia podcasts here. CREDITS: Host: Claire Murphy. Claire also hosts Mamamia's daily news podcast, The Quicky. Executive Producer: Elissa Ratliff Assistant Producer: Emmeline Peterson Audio Producer: Madeline Joannou Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures. Just by reading or listening to our content, you're helping to fund girls in schools in some of the most disadvantaged countries in the world - through our partnership with Room to Read. We're currently funding 300 girls in school every day and our aim is to get to 1,000. Find out more about Mamamia at mamamia.com.au Become a Mamamia subscriber: https://www.mamamia.com.au/subscriber-hubSee omnystudio.com/listener for privacy information.
Nate is joined on this episode by Norfolk County Mayor Amy Martin. Mayor Martin is the kind of Mayor we could all use more of. She's passionate, smart, kind, and she's driven to make a difference in her home community. She served as a counsellor starting in 2018, and she defeated an incumbent mayor this past fall. She is also a product of Norfolk County herself, and at the age of 34, she represents the generational change we very much need with an approach to politics that we very much need. She comes to politics with experience in the nonprofit sector, including stints with the Heart and Stroke Foundation and the MS Society. This is the first in a series of podcasts we plan to do with new civic leaders to hear about the issues in different communities and to highlight a new generation of municipal leadership. Be sure to check back as we continue to post new episodes in this series
Improving your stroke risk factors can reduce your chance of having another stroke. Some factors you can talk to your doctor about, like high blood pressure, type 2 diabetes, cholesterol and atrial fibrillation, or irregular heartbeat. Then there are things that are part of a healthy life, like quitting smoking, avoiding alcohol, and eating well and staying physically active. In this podcast, we talk about these risk factors, and we'll look at a new website to help stroke survivors to eat well and move more, i-Rebound. We speak to stroke lived-experience advocate Meredith Burke, researcher and physiotherapist Dina Pogrebnoy, and registered nurse Fi Camino from StrokeLine.
i-REBOUND: Full Chat With Emma Gee by Stroke Foundation
This podcast was created and is hosted by Sue Bowden (www.moonriverturkey.com.au), a young survivor of stroke. This podcast series is part of Stroke Foundation's Young Stroke Project. Sue was living a full life. She was happily married, pregnant with her first child and training to be a nurse. However, she could sense that something wasn't quite right. Sue is joined with David Cumming, life coach and counsellor at Mindmyself.net. In this episode Sue talks about the passion behind her work in wanting to see more current and relatable information to assist Young Stroke Survivors and their support crews.
This podcast was created and is hosted by Paul Burns, a young survivor of stroke. This podcast series is part of Stroke Foundation's Young Stroke Project. Ash Gordon is a young survivor of stroke and traditional Chinese medicine practitioner. In this episode Paul and Ash discuss the early stages of Ash's stroke and long recovery, getting back to study after his stroke, how the University accommodated him, mental health, goal setting…and more!
This podcast was created and is hosted by Paul Burns, a young survivor of stroke. This podcast series is part of Stroke Foundation's Young Stroke Project. Beth has a strength and determination that has seen her to go on to smash it after the stroke she suffered when she was 19 years old. She's organised a major fundraiser for the Stroke Foundation. She has also completed her studies in Nursing and has just begun her first role in the industry. She talks about how she accomplished all this whilst dealing with post stroke symptoms such as fatigue and navigating the associated changes to her social life that an event like a stroke brings.
In this episode we discuss a recent paper published in The Canadian Journal of Cardiology entitled Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease and co-authored by a national team of Canadian expertsWe are joined today by the two of the authors, Dr Sonia Anand and Dr. Eric KaplovitchDr. Sonia Anand is Professor of Medicine and Epidemiology, and a Vascular Medicine specialist at Hamilton Health Sciences. She holds the Canada Research Chair in Ethnic Diversity and Cardiovascular Disease (Tier 1) and is the Heart and Stroke Foundation of Ontario/Michael G DeGroote Chair in Population Health Research. Dr. Anand is a senior scientist at the Population Health Research Institute, and Director of the Chanchlani Research Centre, McMaster University. Her research focuses on the environmental and genetic determinants of vascular disease in populations of varying ancestral origin, women and cardiovascular disease, and peripheral artery disease. Dr. Anand graduated as a Doctor of Medicine from McMaster University in 1992. She completed internal medicine training at McMaster University and a Fellowship of the Royal College of Physicians and Surgeons of Canada, Ottawa, in 1996. Dr. Anand completed a thrombosis fellowship in 1997-98 under the supervision of Dr. Jeffrey Ginsberg at McMaster University, and Vascular Medicine Fellowship under the supervision of Dr. Mark Creager at the Brigham and Women's Hospital, Harvard University, Boston, USA in 2000-01. Dr. Anand received her Master's degree in clinical epidemiology in 1996 and PhD. in Health Research Methodology in 2002 under the supervision of Dr. Salim Yusuf, both at McMaster University. Dr. Anand was Principal Investigator of the WAVE trial in peripheral artery disease (PAD) patients, is the PAD Lead Investigator of the COMPASS trial, and is an executive committee member of the VOYAGER PAD trial. Dr. Anand's large-scale research programs include multi-centre prospective cohort studies and randomized trials. She has published more than 400 peer-reviewed, high-impact papers. In 2019 Dr. Anand was inducted as a Fellow to the Canadian Academy of Health Sciences. In 2021-22 Dr. Anand Co-chaired the Canadian Cardiovascular Society Peripheral Artery Disease Guidelines.ANDDr. Eric Kaplovitch completed his Internal Medicine training at the University of Toronto before completing additional Vascular Medicine and Thrombosis training at both McMaster University and the University of Toronto, as well as a subsequent fellowship at the HoPingKong Centre of Excellence with a focus on new models of care for patients with arterial and venous disease states. He currently practices Thrombosis and Vascular Medicine at the University Health Network and the Sinai Health System in Toronto and serves as the Quality and Safety Lead for the Blood Disorders program. Dr. Kaplovitch's current academic interests include optimizing the choice and intensity of vascular protective agents following severe vascular events, the organization of vascular care within local and regional health systems, as well as the teaching of vascular medicine and thrombosis to front-line clinicians. He served as co-lead for the antithrombotics section of the recent CCS guidelines on peripheral arterial disease. Follow us on Twitter: Thrombosis Canada: @thrombosiscanDr Sonia Anand: @DrSoniaAnand1Dr Eric Kaplovitch: @kaplovitchSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
Alan speaks with Manuel Arango, director of health policy and advocacy at the Heart and Stroke Foundation. See omnystudio.com/listener for privacy information.
On Episode 17 of the Stroke Alert Podcast, host Dr. Negar Asdaghi highlights two articles from the June 2022 issue of Stroke: “Vitamin D Enhances Hematoma Clearance and Neurologic Recovery in Intracerebral Hemorrhage” and “Acute Ischemic Stroke, Depressed Left Ventricular Ejection Fraction, and Sinus Rhythm: Prevalence and Practice Patterns.” She also interviews Dr. Bruce Campbell on his article “Role of Intravenous Thrombolytics Prior to Endovascular Thrombectomy.” Dr. Negar Asdaghi: Let's start with some questions. 1) Is vitamin D that golden key to recovery from intracerebral hemorrhage? 2) Endovascular therapies seem to have prevailed where thrombolytics have failed. In the era of fast and furious thrombectomy, what is the role of pre-thrombectomy thrombolysis? 3) And finally, 20 years of clinical research has failed to demonstrate the superiority of anticoagulation over antiplatelet therapies for treatment of patients in sinus rhythm with low left ventricular ejection fraction, and yet, our practice patterns have not changed. Why do we remain resolute in prescribing anticoagulation despite the lack of evidence? We're back here to tackle the toughest questions with our Stroke Alert Podcast because this is the latest in Stroke. Stay with us. Dr. Negar Asdaghi: Welcome back to another extremely motivating Stroke Alert Podcast. My name is Negar Asdaghi. I'm an Associate Professor of Neurology at the University of Miami Miller School of Medicine and your host for the monthly Stroke Alert Podcast. The June 2022 issue of Stroke contains a number of interesting articles. As part of our Advances in Stroke, we have two articles, one on the topic of cost-effectiveness of stroke care to inform health policy and the second on the current state and the future of emerging stroke therapies. As part of our Original Contributions category, we have an interesting study by Dr. [Ben] Assayag and colleagues from the Department of Neurology at Tel Aviv Sourasky Medical Center, where we learned that just over 10% of patients with TIA and stroke developed post-traumatic stress disorder, or PTSD. Higher presenting stroke severity, preexisting white matter disease, and having anxious coping styles are risk factors for development of post-stroke PTSD. Dr. Negar Asdaghi: In another Original Contribution, by Dr. Daehoon Kim and colleagues from Yonsei University College of Medicine in Seoul, South Korea, we read with interest on the topic of whether or not we should be anticoagulating frail patients with atrial fibrillation. In this large population-based cohort, which included patients with atrial fibrillation older than 65 years of age with frailty as defined by a score of equal or greater than five on Hospital Frailty Risk Score, we learned that despite their frailty, patients with atrial fibrillation still significantly benefit from oral anticoagulation therapy. In this study, those treated with anticoagulation had lower net adverse clinical events as compared to those untreated. We also learned that direct oral anticoagulants provided lower incidence of stroke, bleeding, and mortality over Coumadin. This paper really provided practical information on treatment of frail patients with atrial fibrillation. So, I encourage you to review these papers in addition to listening to our podcast today. Later in the podcast, I have the great pleasure of interviewing Dr. Bruce Campbell from University of Melbourne in Australia on an especially timely topic, that is the role of intravenous thrombolytics prior to endovascular therapy. Dr. Campbell is a leading authority on the topic, and his interview does not disappoint. But first, with these two articles. Dr. Negar Asdaghi: In the setting of intracerebral hemorrhage, or ICH, aside from the primary brain insult that occurs at the time of hemorrhage, secondary brain injuries continue for days and sometimes to months mostly due to the pathological response of the brain to byproducts of hematoma lysis or RBC degradation products. Today, the majority of spontaneous ICH cases are not surgically evacuated, so we rely on the body's own ability to clear blood for hematoma clearance, and obviously the faster the clearance, the better the outcome. Erythrophagocytosis by monocyte-derived macrophages contributes to hematoma clearance and ultimately to the functional recovery from ICH. So, it's conceivable that therapeutic approaches to enhance the endogenous erythrophagocytosis can potentially improve ICH outcomes. Vitamin D has been known to have variety of functions within the central nervous system, and it turns out that it may also be one such therapeutic option to improve the much needed erythrophagocytosis in intracerebral hemorrhage. Dr. Negar Asdaghi: In the current issue of the journal, in the study titled "Vitamin D Enhances Hematoma Clearance and Neurologic Recovery in Intracerebral Hemorrhage," a group of researchers led by Dr. Jiaxin Liu from the Department of Surgery at Queen Mary Hospital at the University of Hong Kong studied the effects of oral vitamin D administered two hours after the induction of hematoma in a rodent model of ICH using direct collagenase injection into the striatum of the mouse. Eighty-nine young mice and 78 middle-aged mice were included in the study and randomly divided into three groups. Group one were sham-operated mice; group two, ICH mice treated with vehicle, which was corn oil; and group three, vitamin D-treated ICH mice. In the third group, 1000 international unit per kg of vitamin D diluted in corn oil was administered orally using a pipette two hours after the induction of ICH to mice, and then daily afterwards. And here are their top three findings of this study. Dr. Negar Asdaghi: Number one, vitamin D-treated mice did better than vehicle on two neurobehavioral tests that were completed in the study. On the cylinder test, treatment with vitamin D significantly alleviated the asymmetric usage of four limbs at day seven, and vitamin D elongated the duration that the mice could run on the accelerated rod at day 10 on the rotarod test. Dr. Negar Asdaghi: Number two, in terms of hematoma resolution and perihematoma edema, it's an issue that we deal with, with ICH, they used MRI imaging for edema measurement on T2-weighted images, and then sacrificed the mice and used digital quantification of hematoma volume with fresh brain specimens. And they found that treatment with vitamin D significantly alleviated both the ICH-associated brain swelling on MR and resulted in significant reduction in hematoma volume on the fresh brain specimens when compared with the vehicle-treated group at day three and day five. Dr. Negar Asdaghi: And finally, their third main finding is in terms of erythrophagocytosis. So, the pathway that is mediated by the monocyte-derived macrophages is an endogenous pathway, that is, PPAR-γ (which stands for peroxisome proliferator-activated receptor γ) and its downstream scavenger receptor CD36 mediated. This pathway is essential for directing the endogenous erythrophagocytosis. Using flow cytometry, they found that vitamin D-treated mice had more mature macrophages expressing the scavenger receptor CD36, which was not expressed by the undifferentiated monocytes. Dr. Negar Asdaghi: Western blot analysis confirmed that vitamin D treatment increased the tissue levels of CD36 and the upstream PPAR-γ levels in the brain at day five after collagenase model. Locally, vitamin D-enriched phagocytes that were positive for PPAR-γ and CD36 in the perihematoma regions. So, in summary, vitamin D increased the number of mature macrophages rather than undifferentiated monocytes in the perihematoma region and accelerated the differentiation of reparative macrophages from bone marrow-derived monocytes. So, bottom line is that in vitamin D, we have a simple, accessible, and well-tolerated agent to improve both the ICH outcomes and enhance hematoma resolution, but this we all observed in rodents. So, we stay tuned with interest to find out whether the same success will be seen in humans treated with vitamin D after intracerebral hemorrhage. Dr. Negar Asdaghi: Patients with depressed left ventricular ejection fraction, or low EF, are at risk of development of ischemic stroke even if they remain in sinus rhythm. The optimal antithrombotic treatment for these patients is still unknown. Over the past two decades, we have a number of randomized trials studying the efficacy of oral anticoagulation, predominantly Coumadin, over aspirin therapy in prevention of all forms of stroke, that is ischemic and hemorrhagic, and death in patients with a low EF in sinus rhythm. Dr. Negar Asdaghi: The meta-analysis of WASH, HELAS, WATCH, and WARCEF trials showed that treatment of low ejection fraction patients in sinus rhythm with Coumadin does reduce the subsequent risk of stroke, but it comes at the cost of a higher major bleeding risk in this population. The COMMANDER HF clinical trial published in New England Journal of Medicine in October 2018 studied whether low-dose rivaroxaban at 2.5 milligram BID was superior to placebo in patients with recent worsening of chronic heart failure, reduced ejection fraction, coronary artery disease, but no atrial fibrillation, and very similar to its prior counterparts, it did not show that rivaroxaban was associated with a lower rate of combined death, myocardial infarction, or stroke as compared to placebo. But very similar to prior studies, it also showed that rivaroxaban-treated patients had a lower risk of subsequent ischemic stroke. This poses a conundrum for stroke neurologists treating patients with this condition, especially after they present with an embolic-appearing stroke. So, the question is, how often do we encounter this situation, and what do we do in routine practice? We know that when there is equipoise, there's practice variation. Dr. Negar Asdaghi: In the current issue of the journal, in the study titled "Acute Ischemic Stroke, Depressed Left Ventricular Ejection Fraction, and Sinus Rhythm," Dr. Richa Sharma from the Department of Neurology at Yale School of Medicine and colleagues examined the prevalence of heart failure with sinus rhythm among hospitalized patients with acute ischemic stroke and the physician's practice patterns with regard to the choice of antithrombotics in this population. Dr. Negar Asdaghi: So, let's look at their study. The study was comprised of five separate study cohorts of hospitalized acute ischemic stroke patients in the Greater Cincinnati Northern Kentucky Stroke Study for the year 2005, 2010, and 2015, and then four additional academic hospital-based cohorts in the United States during different timeframes. These were the Massachusetts General Hospital from 2002 to 2016, Rhode Island Hospital from 2016 to 2018, Yale-New Haven Hospital 2015 to 2017, and Cornell Acute Stroke Academic Registry from 2011 to 2018. All of these cohorts combined contributed to the 19,155 total number of patients in this study, which included over 14,000 patients that had documented left ventricular ejection fraction. Amongst those, 1,426 had a depressed EF and were included in this study. The investigator obviously excluded those with documented atrial fibrillation and flutter. And so the sample size for this analysis was 805 patients. And here are their main results. Dr. Negar Asdaghi: The overall prevalence of this condition, that is low ejection fraction and sinus rhythm, among hospitalized acute ischemic stroke patients was 5%. It varied slightly between the different cohorts in this study from 4 to 6%. In terms of the antithrombotic treatment patterns, this information was available in close to 500 patients in the cohort. Overall, 59% of patients were discharged on an antiplatelet treatment alone, and 41% on anticoagulation. But these percentages significantly varied between the different institutions and was as low as 22% in one of the cohorts and as high as 45% in another cohort. Dr. Negar Asdaghi: So, what were the factors that were associated with the use of anticoagulation at discharge? They found that the absolute percentage of left ventricular ejection fraction and the presenting NIH Stroke Scales were associated with anticoagulation use. That is, the lower the percentage of EF and the higher the presenting NIH Stroke Scale, the more likely physicians were to discharge the patients on an anticoagulation in univariate analysis, but in multivariate analysis, only the study site and presenting NIH Stroke Scale over eight were independently associated with anticoagulation use. Dr. Negar Asdaghi: Now, interestingly, 2002 to 2018, which was their overall study period, was a time during which some of the largest and neutral randomized trials on the topic of anticoagulation versus antiplatelet were published, including the WATCH and the WARCEF trial. But the authors found no temporal variation in anticoagulation practice patterns before and after the publication of the results of these trials. So, it appears that we didn't change our minds. So, overall, we have some important takeaway messages from this study. We learned that 5% of hospitalized acute ischemic stroke patients have low left ventricular ejection fraction and remain in sinus rhythm without atrial fibrillation. Today, over 40% of patients with this condition are anticoagulated at discharge despite the results of the randomized trials, but the practice is widely variable among different institutions, and a higher presenting NIH Stroke Scale is a significant predictor of anticoagulation use at discharge in this population. Dr. Negar Asdaghi: Almost 20 years after the approval of intravenous thrombolysis for treatment of patients with acute ischemic stroke, endovascular therapy was approved for treatment of select ischemic stroke patients with a large vessel occlusion. The two treatments are, therefore, entangled, as one was the standard of care while the second one was being tested. Therefore, all endovascularly treated patients enrolled in randomized trials would've received intravenous thrombolysis if eligible. Now, with the overwhelming success of endovascular therapy in achieving reperfusion in areas where IV thrombolysis has drastically failed, there're still critical questions regarding the added value of IV thrombolysis to endovascularly treated patients. The critical question remains as to whether eligible ischemic stroke patients who have immediate access to endovascular thrombectomy should receive prior IV thrombolysis, or should we skip the thrombolysis step altogether and just move to the angio suite as fast as possible. And there are, of course, arguments for and against each approach. Dr. Negar Asdaghi: In this issue of the journal, in an invited topical review titled "The Role of Intravenous Thrombolytics Prior to Endovascular Thrombectomy," we learn about these arguments as the authors go through a comprehensive review of the current literature on this issue. I'm joined today by the first author of this review, Dr. Bruce Campbell, to discuss this paper. Dr. Campbell absolutely needs no introduction to our Stroke listeners. He's a professor of neurology and head of neurology and stroke at Royal Melbourne Hospital, University of Melbourne, in Australia. He's a pioneer in the field of acute stroke therapies and acute neuroimaging. He has served as the lead investigator of multiple landmark randomized trials, including EXTEND-IA and EXTEND-IA TNK, and holds multiple leadership roles. He's the clinical director of the Stroke Foundation and co-chairs the Australian Stroke Guidelines Working Party and the coordinator of the National Brain School Training Program for Neurologists in Training. And, of course, last but not least, he's my friend. So, I'm delighted to welcome him to our podcast today. Top of the morning to you, Bruce, 6:00 a.m. in Melbourne. That's quite some dedication. Thank you for being here. Dr. Bruce Campbell: It's great to be with you. Thanks for the invitation. Dr. Negar Asdaghi: Congrats on the paper, really exciting topic. So, let's just start with this question as part of a case. We have a patient with an M1 occlusion, a large clinical syndrome presenting two hours out from their symptom onset, and we are at a hospital where the angio suite is ready. What are some of the benefits of basically spending time in giving IV thrombolytics first rather than quickly going to the angio suite? Dr. Bruce Campbell: I think a key element of this case is that the patient has presented directly to a hospital with immediate access to thrombectomy. Thrombolytic used in drip-and-ship transfer patients really isn't controversial, and the recent randomized trials excluded them. So, the debate's all about this context of bridging thrombolytics in patients presenting directly to a comprehensive stroke center. And you mentioned spending time giving lytics, but in fact, if you do things in parallel, that shouldn't be the case. It shouldn't delay thrombectomy if you go and give thrombolysis. Dr. Bruce Campbell: So, the general principle is that getting the artery open faster by any means is better, and IV thrombolytic certainly has the potential to open the artery before thrombectomy in a proportion of patients, perhaps not that many, but it may also facilitate the thrombectomy. So, in the randomized trials, reperfusion after the thrombectomy was significantly better when patients had had bridging thrombolytic despite a low rate of pre-endovascular reperfusion. Other reasons for giving the lytics are the potential safety net it provides if the thrombectomy procedure is unexpectedly delayed or fails to get the artery open, and there's also this potential for lytics to dissolve distal embolic fragments and perhaps improve microvascular reperfusion. Dr. Negar Asdaghi: So, great. So, let me summarize for our listeners what you mentioned. First off, so these are arguments in favor of giving lytics. As you mentioned, we're not really wasting time. These processes occur in parallel, so it's not like we're wasting time in giving a therapy that is potentially not as efficacious as thrombectomy is. And number two, we have improved the possibility of early reperfusion, perhaps, with the lytics. And if there are some fragments or distal clots that thrombectomy wouldn't have reached, then the lytics would. And then also there is also the chance that the thrombectomy might have failed in difficult access, and so on and so forth, and at least the patient has some chance of revascularization with the lytics. So, if these are the arguments for giving lytics, what are the arguments against giving lytics in this scenario? Dr. Bruce Campbell: The main argument is the potential to reduce both the intracerebral and systemic hemorrhagic complications. There's also potential cost saving by skipping thrombolytics. That's probably more relevant in low-resource settings, particularly when relatives may have to pay for the thrombolytic before treatment is initiated, and that can be burdensome and also potentially delay the thrombectomy. There's a theoretical concern about thrombus fragmentation with lytics and potential migration of the clot out of reach of the thrombectomy or to new territories. But final reperfusion, as I mentioned, was, on average, better with the patient having a lytic on board in the randomized trials. Dr. Negar Asdaghi: Perfect. And I want to highlight this issue of thrombus fragmentation because I think our readers will read more and more about this idea of, as you mentioned, fragmentation will potentially make an accessible clot for thrombectomy inaccessible. But I see that later in our questions, we're going to address that as part of the findings of randomized trials as well. So, these are some of the arguments for and against. And before we go to the randomized trials, I'd like to get an overview of what we knew as part of observational studies and non-randomized studies prior to more recent randomized trials on this topic. Dr. Bruce Campbell: There've been a couple of nice systematic reviews and meta-analyses of the observational data, and notably in most of these studies, the direct thrombectomy patients had contraindications to lytics, and that introduces confounding factors that are difficult to adjust for. For what that's worth, the functional independence, mortality outcomes were better in the bridging patients. Hemorrhage rates weren't always higher with the lytic, and one study by Jonathan Coutinho in JAMA Neurology for the SWIFT and STAR studies showed the opposite despite them having really careful adjustment for all the confounders they could think of. And the meta-analysis by Eva Mistry in Stroke did not detect a difference in symptomatic ICH between the direct and bridging strategies. One thing that should be less affected by the patient characteristics would be the technical efficacy outcomes, and it was interesting that in the observational data, the patients who'd had bridging lytic had higher mTICI 2b-3 rates and also fewer device passes. Dr. Negar Asdaghi: Okay. And now we do have further information with all of these new randomized trials. So, why don't we start with some of the earlier studies, the three, SKIP, DEVT, and DIRECT-MT, and start with those studies first before we move to some more recent European trials. Dr. Bruce Campbell: SKIP was performed in Japan, and it used the lower 0.6 milligram per kilogram dose of alteplase that's standard there, and DEVT and DIRECT-MT were performed in China. All three of them showed numerically similar functional outcomes with slight trends favoring direct thrombectomy. SKIP had a smaller sample size and did not meet its non-inferiority criteria, and the other two trials did meet their specified non-inferiority margin, but it could be argued those margins were overly generous. If you think about non-inferiority trials, we generally try to set a margin for non-inferiority such as lower 95% confidence interval for the trial intervention would sacrifice up to 50% of the reference treatment effect. And it's difficult to estimate the effect of alteplase in this specific population. But if you think of the Emberson meta-analysis of alteplase, overall zero to three hours alteplase versus placebo has a 10% effect size and mRS 0-1, three to four and a half hours of 5% effect size. And we regard that as clinically important. So, half of 5%, 2.5%, is a lot tighter margin than any of the direct randomized trials employed. Dr. Negar Asdaghi: So, Bruce, let me recap what you just mentioned. Two out of the three earlier trials seem to suggest that perhaps skipping IV therapy is the way to go rather than bridging as these two trials met the non-inferiority criteria if we believe that non-inferiority margins you mentioned. And now we have a couple of more trials, more recent trials. Can you tell us about these trials please? Dr. Bruce Campbell: MR CLEAN-NO IV in a European population did not demonstrate non-inferiority, and the point estimate slightly favored bridging. Interestingly, in that trial, the symptomatic intracerebral hemorrhage risk, which was one of the main drivers for trying this strategy, was 5.9% in the direct and 5.3 in the bridging group. So, there's no hint of benefit from dropping the lytic on that metric. SWIFT-DIRECT was more selective in only enrolling internal carotid and M1 occlusions, which had a lower chance of early recanalization with lytic. But the protocol also specified giving the full dose of lytic. In the other trials, it seems the alteplase infusion was often stopped once the patient was in the angio suite, so the full dose may not have been delivered. And despite very low pre-endovascular recanalization in that selected group in SWIFT-DIRECT, the end of procedure reperfusion was significantly better in the bridging group, which is a consistent finding across the trials and suggests that the lytic may improve the thrombectomy outcome. Dr. Bruce Campbell: DIRECT-SAFE, the final of those trials, was interesting in that the patients were enrolled roughly 50:50 from Australia, New Zealand, versus Asia. And in contrast to the original three randomized trials in Asian patients, DIRECT-SAFE found a significant benefit of bridging lytic in Asian patients. So, it'd be very interesting to see the results of the IRIS individual patient data meta-analysis, but we may not find a difference in Asian versus Caucasian patients despite those initial trials and despite substantial differences in the prevalence of intracranial atherosclerosis, which has often been proposed as something that would increase the risk of having bridging thrombolytic on board. Dr. Bruce Campbell: The original study level estimate of symptomatic hemorrhage had a borderline significant 1.8% absolute reduction in the direct group. Whether those data were not all core lab adjudicated and the final analysis may show a smaller difference than that. Notably, given that trend with symptomatic intracerebral hemorrhage, mortality did not differ significantly, and, in fact, the trend favored bridging patients. So, the symptomatic hemorrhage slight trend into increase did not translate into any hint of increased mortality. Dr. Negar Asdaghi: So, Bruce, a lot of information, and I need a recap for me. So, let me try to recap some of the things you said, and please jump in. So, so far, the newer data really basically don't show us any convincing evidence that skipping is the way to go, and direct endovascular we really don't have data in favor of going directly to the angio suite. And the jury is still out regarding an increase in the symptomatic intracerebral hemorrhage rate amongst those that actually are pre-treated with IV therapy. Is that correct? Dr. Bruce Campbell: That's correct. So, none of the three recent trials met their non-inferiority margins. And again, we had this issue of relatively generous non-inferiority margins, and the symptomatic hemorrhage, it would make sense that there's a small difference, but it's not really been borne out in the data to be statistically significant at this stage. And again, this individual patient data meta-analysis is keenly awaited to get the most accurate estimate on that. Dr. Negar Asdaghi: So, while we wait that, I'm going to digress a little bit and ask you a question that's not addressed in the paper that you have in this issue of the journal, and that's the CHOICE trial. So, by now, we have the results of CHOICE trial. Do you mind first give us a brief overview of what CHOICE was and how you feel that the results of CHOICE would affect this field of direct versus bridging in general? Dr. Bruce Campbell: CHOICE is a very interesting study in that it tested giving the intra-arterial lytic at the end of a thrombectomy procedure that had achieved an mTICI 2b or better, which is what we traditionally regarded as angiographic success. The idea was to improve microvascular flow, and that may be the case. The trial was terminated early due to logistic reasons and showed a very large effect size that requires replication. The subgroup analyses are interesting in that the benefits seem to mostly accrue in patients who'd not already had intravenous lytic. Dr. Bruce Campbell: So, perhaps giving the IV lytic before thrombectomy can still benefit patients after the thrombectomy, as well as achieving early recanalization in a proportion of patients and perhaps facilitating the thrombectomy. The other issue to address with the DIRECT trials is that with the exception of a few patients in DIRECT-SAFE, the comparator was alteplase and not tenecteplase. And we have data from EXTEND-IA TNK that tenecteplase bridging is not just non-inferior, but superior to alteplase bridging. There's an ongoing Brazilian trial of exactly that, tenecteplase versus the direct approach, which will be very interesting. Dr. Negar Asdaghi: So, great, Bruce. I just want to repeat this segment again for our listeners. So, CHOICE is a very interesting study, looked at giving intraarterial alteplase to patients after endovascular therapy was completed and after they'd already achieved the complete and successful revascularization, and the trial was terminated early because of logistic reasons. So, we have to keep in mind, this was a smaller study, early termination, but the effect size was pretty large in favor of giving lytics. Dr. Negar Asdaghi: So, what you mentioned is interesting, and I think that it's really worth paying attention to, that the majority of the benefits seem to have occurred from intraarterial thrombolytics in patients that have not been given intravenous lytics prior to endovascular therapy. So, in other words, you need some sort of lytics either before or after the endovascular thrombectomy to achieve that ultimate improved outcome. So, moving forward now from the randomized trials that we have on bridging versus direct thrombectomy, you have mentioned in the paper some interesting subgroups that may benefit or not benefit as much from bridging versus direct thrombectomy. Do you want to elaborate a little more about those subgroup analyses? Dr. Bruce Campbell: The idea of precision selection or individualized treatment is being talked about a lot given there didn't seem to be much overall difference between strategies in the randomized trials, but it's important to note that the randomized trial actually disadvantages the bridging group by delaying lytic until the patient was firstly confirmed eligible for thrombectomy and then consented and randomized. Putting that aside, if we could identify a subgroup who clearly benefit from skipping lytic and, importantly, identify them without delaying lytic for those who likely benefit, that's clearly attractive. Dr. Bruce Campbell: Currently, I'd say we have not identified that kind of subgroup, and the planned IRIS individual patient data meta-analysis will be critical for that. Patients with a large ischemic core are one potential group where there's a high risk of bleeding hypothesized. To date, there is no definitive data to indicate the risk is lower with the direct approach. Patients who need stents certainly may benefit from not having a lytic on board because they often need adjuvant antithrombotics that could increase the bleeding risk. But the question there is whether we can confidently identify those patients before the procedure, and I think that's unclear at this stage. Patients with really large clot burdens and proximal occlusions have sometimes been said not to benefit from IV lytic based on the low rates of pre-endovascular reperfusion, but the randomized trials really hinted other benefits like this potential facilitative thrombectomy. So, that hypothesis may be insecure as well. Dr. Negar Asdaghi: And how about age? Have you come across and has there been any signal towards an impact or interaction between age and benefit from pre-endovascular thrombectomy and thrombolytics? Dr. Bruce Campbell: It's an interesting question because age has not generally been a treatment effect modifier in previous stroke studies with thrombolytics and thrombectomy, and the individual direct thrombectomy trials that have reported subgroups haven't shown any convincing heterogeneity by age. There's certainly no indication that older patients are at risk from bridging in what I've seen so far. Dr. Negar Asdaghi: So, this question comes up in clinical practice all the time, that a person's older, perhaps more atrophy, more vascular risk factors and white matter disease, and they're more prone, so to speak, of having a symptomatic intracerebral hemorrhage. So, what you're saying is, from the data we have, there's really no signal in favor of withholding pre-thrombectomy lytics in this population. So, it's important to know this. Bruce, what should be our final takeaway message from this study? Dr. Bruce Campbell: I tend to agree with the recent European Stroke Organization and ESMINT guideline that for now, patients should receive lytic as early as possible and in parallel with the decision to perform thrombectomy such that neither treatment delays the other. I think if we can identify a subgroup that benefits from direct thrombectomy, and that's confirmed in the individual patient data and meta-analysis, and we can identify them without disadvantaging the majority of patients, and also that the ongoing improvements in IV lytic strategies don't render the existing trial data obsolete, then we may, in future, skip lytic for some patients, but we are not there yet. Dr. Negar Asdaghi: So, that's amazing, Bruce. We look forward to reviewing the paper and individual data meta-analysis and interviewing you, hopefully at a better hour your time, on that. Thank you very much for joining us on the podcast today. Dr. Bruce Campbell: Thanks again for the invitation. It's been great talking to you. Dr. Negar Asdaghi: Thank you. Dr. Negar Asdaghi: And this concludes our podcast for the June 2022 issue of Stroke. Please be sure to check out this month's table of contents for the full list of publications, including three very interesting images that are presented as part of a new article type, Stroke Images, and a special report in Comments and Opinions section on "Bias in Stroke Evaluation: Rethinking the Cookie Theft Picture." June is the month of Pride, and in spirit of equality, we hope to do our part to reduce all biases in stroke processes of care, diagnosis, and outcomes as we continue to stay alert with Stroke Alert. Dr. Negar Asdaghi: This program is copyright of the American Heart Association, 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, visit AHAjournals.org.
This podcast was created and is hosted by Paul Burns, a young survivor of stroke. This podcast series is part of Stroke Foundation's Young Stroke Project. Gustavo Zaera is a Spanish born, multilingual, Norwegian technology entrepreneur who has dealt with many challenges including a brain tumour in 2013. In this episode we chat about his approach to life, dealing with emotions and how his early childhood experiences forged the resilience that helped him deal not only with his diagnosis and treatment but go on to continue to succeed!
This podcast was created and is hosted by Paul Burns, a young survivor of stroke. This podcast series is part of Stroke Foundation's Young Stroke Project. Nichola Browning is a registered nurse who has worked in both the UK and Australia. She's worked in Critical Care, Neurosciences, Traumatic and Acquired Brain Injury, Rehabilitation, Paediatrics, Cardiothoracics and Youth Mental Health She is also the Mum of a young stroke survivor, Beth, who suffered her injury at the age of 19. In this episode, Paul chats to Nichola about the effect this had on her whole family, how she managed “burn out” and how she continues to move forward.
This podcast was created and is hosted by Paul Burns, a young survivor of stroke. This podcast series is part of Stroke Foundation's Young Stroke Project. Rob Goyen is an ambitious endurance Athlete who is always chasing the next achievement. Between running successful businesses in Asia or competing in adventure races, Rob loves pushing himself. We find out what drives him to succeed and what motivated him to compete in 250km Ultramarathon on the 10th anniversary of his Stroke.
For more details, visit the #DrGPCR Podcast Episode #70 page https://www.drgpcr.com/episode-70-with-dr-stephen-ferguson/ ------------------------------------------- About Dr. Stephen Ferguson Dr. Stephen Ferguson is a Professor in the Department of Cellular and Molecular Medicine at the University of Ottawa. He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr. Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994). He did his postdoctoral training with Dr. Marc G. Caron at Duke University (1994-1997), where he and his colleagues investigated the role of G protein-coupled receptor kinases and beta-arrestin in regulating G protein-coupled receptor endocytosis, trafficking, and signaling. He has held four Canada Research Chairs since 2001 and was previously a Heart and Stroke Foundation of Canada MacDonald Scholar (1998-2003) and Heart and Stroke Foundation of Ontario Career Investigator (2003-2016). He was a recipient of Canada's Top 40 under 40 award in 2004 and received Queen Elizabeth II, Diamond Jubilee Medal, in 2012. He has also received both Junior (2001) and Senior (2005) investigator awards from the Pharmacological Society of Canada. Most recently, in 2021, he was elected as a Fellow of the Canadian Academy of Health Science (FCAHS). His research career has focused on the investigation of the regulation of G protein-coupled receptors signaling mechanisms in health and disease. He currently holds multiple research grants from the Canadian Institutes of Health Research (CIHR) for his research investigating the role of metabotropic glutamate receptor signaling in Huntington's and Alzheimer's disease. Dr. Stephen Ferguson on the web Carlton University Canada Research Chairs Twitter ResearchGate LinkedIn Great Lakes GPCR Retreat on the web 21st Great Lakes GPCR Retreat More about previous GPCR Retreat meetings ------------------------------------------- Are you a #GPCR professional? - Register to become a Virtual Cafe speaker http://www.drgpcr.com/virtual-cafe/ - Subscribe to our Monthly Newsletter http://www.drgpcr.com/newsletter/ - Listen and subscribe to #DrGPCR Podcasts http://www.drgpcr.com/podcast/ - Support #DrGPCR Ecosystem with your Donation. http://www.drgpcr.com/sponsors/ - Reserve your spots for the next #DrGPCR Virtual Cafe http://www.drgpcr.com/virtual-cafe/ - Watch recorded #DRGPCR Virtual Cafe presentations: https://www.youtube.com/channel/UCJvKL3smMEEXBulKdgT_yCw - Share your feedback with us: http://www.drgpcr.com/audience-survey/
For more details, visit the #DrGPCR Podcast Episode #69 page http://www.drgpcr.com/episode-69-history-of-the-gpcr-retreat-with-dr-stephen-ferguson/ ------------------------------------------- About Dr. Stephen Ferguson Dr. Stephen Ferguson is a Professor in the Department of Cellular and Molecular Medicine at the University of Ottawa. He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr. Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994). He did his postdoctoral training with Dr. Marc G. Caron at Duke University (1994-1997), where he and his colleagues investigated the role of G protein-coupled receptor kinases and beta-arrestin in regulating G protein-coupled receptor endocytosis, trafficking, and signaling. He has held four Canada Research Chairs since 2001 and was previously a Heart and Stroke Foundation of Canada MacDonald Scholar (1998-2003) and Heart and Stroke Foundation of Ontario Career Investigator (2003-2016). He was a recipient of Canada's Top 40 under 40 award in 2004 and received Queen Elizabeth II, Diamond Jubilee Medal, in 2012. He has also received both Junior (2001) and Senior (2005) investigator awards from the Pharmacological Society of Canada. Most recently, in 2021, he was elected as a Fellow of the Canadian Academy of Health Science (FCAHS). His research career has focused on the investigation of the regulation of G protein-coupled receptors signaling mechanisms in health and disease. He currently holds multiple research grants from the Canadian Institutes of Health Research (CIHR) for his research investigating the role of metabotropic glutamate receptor signaling in Huntington's and Alzheimer's disease. ------------------------------------------- Dr. Stephen Ferguson on the web Carlton University Canada Research Chairs Twitter ResearchGate LinkedIn ------------------------------------------- Great Lakes GPCR Retreat on the web 21st Great Lakes GPCR Retreat More about previous GPCR Retreat meetings ------------------------------------------- We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together. Fill out the Ecosystem waitlist form today to be the first to explore our brand new and improved space! For more details, visit our website http://www.DrGPCR.com/Ecosystem/.
This podcast was created and is hosted by Paul Burns, a young survivor of stroke. This podcast series is part of Stroke Foundation's Young Stroke Project. In the first episode, Paul talks with Saran Chamberlain, who has worn many different hats in her life and has always said “never say no” to taking something on. Her Stroke may have changed her course but certainly hasn't stopped her.
The medical after-effects of a stroke can be mild or severe. But for young survivors, the consequences of returning to their lives after a stroke, can be just as devastating. In fact, only half of stroke patients under the age of 65 ever return to work – and far more cope with depression, anxiety, and extreme fatigue.On today's episode, Heather meets with Dr. Aleksandra Pikula, a pioneer in the field of stroke in young adults. They discuss the latest research, including a new study led by Dr. Pikula, looking at how lifestyle interventions post stroke may help to improve long-term outcomes. Plus, we hear from two of Dr. Pikula's patients to gain a deeper perspective on how they are reclaiming their lives and a nurse practitioner in the stroke unit, about what it's like when a Code Stroke is called. Featuring: Dr. Aleksandra Pikula, Neurologist, Clinician Investigator and Director of Stroke Research with Krembil Brain Institute at UHN, and Associate Professor of Medicine at the University of Toronto.Special thanks to La Croix Calloo, Marianne Fedunkiw, and Tim Stewart for sharing their stories.To hear more from La Croix and Marianne, listen to their full stories here: https://www.uhn.ca/Krembil/Complex-Brain-Podcast/ Additional Resources:Krembil Brain Institute Stroke Prevention Clinic Heart and Stroke Foundation of Canada Canadian Partnership for Stroke RecoveryUniversity of Toronto – Stroke Videos:‘Krembil Minute' showcasing Krembil Brain Institute's world class stroke teamDr. Timo Krings, head of neuroradiology, imaging and intervention at Krembil Brain Institute and the Joint Department of Medical Imaging at UHN, on why he loves his job.
This podcast was created and is hosted by Sue Bowden (www.moonriverturkey.com.au), a young survivor of stroke. This podcast series is part of Stroke Foundation's Young Stroke Project. Sue was living a full life. She was happily married, pregnant with her first child and training to be a nurse. However, she could sense that something wasn't quite right. Sue is joined with David Cumming, life coach and counsellor at Mindmyself.net. In this episode, Sue talks about how she longed to be recognised as a young person who needed to be engaged in an age and culturally appropriate way during her rehabilitation and given more opportunity to express herself.
This podcast was created and is hosted by Sue Bowden (www.moonriverturkey.com.au), a young survivor of stroke. This podcast series is part of Stroke Foundation's Young Stroke Project. Sue was living a full life. She was happily married, pregnant with her first child and training to be a nurse. However, she could sense that something wasn't quite right. Sue is joined with David Cumming, life coach and counsellor at Mindmyself.net. In this episode Sue talks about recognising and understanding a new way of being after her stroke and what other significant events had happened at that time.
Professor Bruce Campbell talks about stroke with the abc by Stroke Foundation
Tuesday and Tim are joined by Dr. Robert Strang, Nova Scotia's Chief Medical Officer of Health, where they discuss the topic on EVERYONE'S MIND these days, COVID (and the Omicron variant!), his personal leadership, and public health. As the one leading the charge of the response to the COVID-19 pandemic in Nova Scotia, how does he continue to hold his centre and what is he learning?About Dr. Robert Strang:Dr. Robert Strang is Chief Medical Officer of Health in Nova Scotia appointed in August 2007. He received his medical degree from University of British Columbia (UBC) and completed Family Practice and Public Health and Preventive Medicine residencies at UBC.As Chief Medical Officer of Health, he has provided leadership around the renewal of the public health system in Nova Scotia as well as raising awareness around the importance of creating policies and environments that support better health for Nova Scotian families and communities.He is passionate about public health and has worked with non-government organizations such as Smoke Free Nova Scotia, Heart and Stroke Foundation and Public Health Association of Nova Scotia.Dr. Strang has an adjunct appointment with Dalhousie University, Department of Community Health and Epidemiology.Resources:Learn more about, and follow, The Outside by visiting and liking all of our channels:Website: www.findtheoutside.comFacebook & Instagram: @findtheoutsideLinkedIn: https://www.linkedin.com/company/findtheoutsideWindhorse Farm transferred to Mi'kmaq in spirit of reconciliationNova Scotia Health See acast.com/privacy for privacy and opt-out information.
This episode is sponsored by HR Habit Finder Shift. If HR is your jam, this is for you! Kristi Knowles is the Chief Executive Officer of Mother Raw, a brand of delicious, organic, plant-based products on a mission to encourage everyone, everywhere to eat more plants! This mission anchors Kristi's focus to lead the Mother Raw brand to market success in the US and Canada, landing retail listing and partnerships with key grocery players and on-line retailers including Whole Foods, Walmart, Sprouts, Target and other large and niche well-being outlets. Under her leadership, the brand has grown from 300 retail listings in 2018, to 3700+ listings across North America.With the brand promise “Put Good on GoodTM” Mother Raw brings a fresh focus to the dressing, marinade, dip, queso and condiment categories. Known for their clean, natural, allergen friendly and refrigerated offerings, Mother Raw products are enjoyed by fans of real, whole foods. So much so that the brand was recently awarded a Clean Eating Award by Clean Eating Magazine, along with a number of other awards and positive profiles. Kristi joined the company in early 2018 and is proud to lead the growing and talented team responsible for the success of Mother Raw; a team that shares the belief that helping people eat more plants makes both good sense and good business! With more than 25 years of experience as a senior executive with S&P 500 companies including Unilever, Campbell's and Molson Coors, Kristi is known for building brands by defining and executing insightful business strategies that drive business success. As CEO, defining strategic direction, building the Mother Raw team and culture, and designing the overall brand experience, fulfills her desire to unite her years of business experience with her dedication to personal wellness and wellness-related initiatives.Kristi's lifelong passion for health and wellness, combined with a commitment to promote healthier relationships with food, attracted the seasoned executive and busy wife and mom to lead the evolution of Mother Raw.Inspired to always “Lead with Heart” Kristi has a focus to be mindful of what makes both business sense and what speaks to her heart. She is also proud to volunteer her time and expertise as an Advisory Board member with The Heart and Stroke Foundation and she was most recently appointed to the Board of Directors for Plant-Based Foods of Canada.Articles that profile Kristi and the evolution of Mother Raw showcase the wins for the scrappy start-up include: Inside an Emotionally Raw Rebranding Story - https://the-message.ca/2020/02/07/inside-an-emotionally-raw-rebranding-story/Her Turn: Meet Kristi Knowles from Mother Raw - https://www.auburnlane.com/her-turn-meet-kristi-knowles-from-mother-raw/Social Impact Heroes: How Kristi Knowles of Mother Raw, is helping to encourage people everywhere to eat more plants https://medium.com/authority-magazine/social-impact-heroes-how-kristi-knowles-of-mother-raw-is-helping-to-encourage-people-everywhere-ca55bc68b53f This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit debcrowe.substack.com
© 2020-2025 Ivy Podcast Discovery LLC
